Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 103, Issue -, Pages 62-77Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.04.020
Keywords
Acute myeloid leukaemia; Cancer immunosurveillance; Immunoediting; Neo-antigens; Immunotherapy; Immune checkpoints; Immune suppression
Categories
Funding
- Leukaemia Foundation
- Cancer Australia
- RBWH Foundation
- Cure Cancer Australia Foundation
- NHMRC
- CCQ
Ask authors/readers for more resources
Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction pathways, transcription factors and epigenetic modifiers. In solid tumours, it is emerging that the genetic landscape of the tumour has a direct effect on the anti-tumour immune responses and response to immunotherapeutic treatment. However, there remains little information as to whether genetic abnormalities affect anti leukemic immune responses. This review discusses current knowledge of AML antigens and immune responses to AML with a particular focus on the role of T cells and natural killer cells. Understanding immune responses to AML has implications for the development and use of immunotherapies to treat AML patients with distinct genetic abnormalities. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available